Attached is the Prescrire International evaluation of the new xanthine oxidase inhibitor
Prescrire International is the English language version of Prescrire a French
drug newsletter that has been published for the past 30 years. Prescrire is highly regarded for its
There have been two head-to-head trials of febuxostat versus allopurinol
published. In these trials based on a composite endpoint of cardiovascular death, non-fatal
myocardial infarction, non-fatal stroke, and non-fatal cardiac arrest, the incidence was 4 to 5
times higher with febuxostat than with allopurinol.
Treatment withdrawals in these trials
due to hepatic abnormalities were 2.8% versus 0.4% with febuxostat and allopurinol
To download this article in PDF format, click here
Don't have Adobe Reader? Click here or the graphic to download it.